Research Analysts Issue Forecasts for BOLT Q1 Earnings

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Equities research analysts at Leerink Partnrs issued their Q1 2026 earnings estimates for shares of Bolt Biotherapeutics in a research note issued to investors on Tuesday, March 25th. Leerink Partnrs analyst D. Graybosch forecasts that the company will earn ($0.36) per share for the quarter. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Bolt Biotherapeutics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.16) EPS and Q4 2026 earnings at ($0.16) EPS.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.38) earnings per share for the quarter, hitting the consensus estimate of ($0.38). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.79 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%.

A number of other equities analysts have also commented on BOLT. HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a report on Tuesday. Stifel Nicolaus lowered their price target on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating on the stock in a research report on Tuesday. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Bolt Biotherapeutics has an average rating of “Hold” and an average target price of $1.13.

Bolt Biotherapeutics Trading Down 3.3 %

Shares of BOLT opened at $0.43 on Thursday. Bolt Biotherapeutics has a 1-year low of $0.38 and a 1-year high of $1.56. The company has a market capitalization of $16.29 million, a P/E ratio of -0.25 and a beta of 0.94. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. The firm’s 50 day simple moving average is $0.47 and its 200 day simple moving average is $0.55.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of institutional investors have recently made changes to their positions in BOLT. Citadel Advisors LLC bought a new stake in Bolt Biotherapeutics in the fourth quarter worth $42,000. Velan Capital Investment Management LP bought a new position in Bolt Biotherapeutics during the 4th quarter worth approximately $27,000. Squarepoint Ops LLC bought a new position in Bolt Biotherapeutics during the 4th quarter worth approximately $26,000. Millennium Management LLC purchased a new position in Bolt Biotherapeutics in the 4th quarter worth approximately $25,000. Finally, FMR LLC lifted its position in Bolt Biotherapeutics by 33.2% in the third quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares during the last quarter. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.